Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced significant site upgrades designed to accelerate drug discovery and development processes for clients worldwide. The investments include a dedicated peptide laboratory in Bengaluru and advanced automation integration across Drug Metabolism and Pharmacokinetics (DMPK) and Direct-to-Biology (D2B) workflows in Hyderabad.
Dedicated Peptide Manufacturing Facility
The new peptide laboratory in Bengaluru represents a strategic expansion into the growing peptide therapeutics market. The facility is designed to produce a wide range of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates, with synthesis scale-up capabilities reaching 800 mmol (millimole).
The laboratory features six automated peptide synthesizers operating in parallel, equipped with robotic arms that significantly reduce project timelines by weeks or even months while ensuring consistent results. The facility integrates Solid-Phase Peptide Synthesis (SPPS), High-Performance Liquid Chromatography (HPLC), and Liquid-Phase purification technologies, working in conjunction with Quality Control (QC) laboratories to provide a seamless transition from discovery to development.
Automation-Driven DMPK Operations
In Hyderabad, Syngene has implemented comprehensive automation across its DMPK operations. The robotic systems for high-throughput sample preparation have delivered substantial operational improvements, reducing turnaround times from five days to three while improving cost efficiency by 30%. The automation upgrades have also tripled sample capacity, providing clients with access to critical pharmacokinetic data significantly faster.
The Direct-to-Biology (D2B) platform further accelerates hit-to-lead and lead optimization processes by combining rapid compound design, miniaturized synthesis, and high-throughput screening. This integrated approach saves at least a week for 24-compound sets and several weeks for larger compound libraries.
Strategic Vision and Market Impact
"At Syngene, we are committed to integrating advanced automation technologies into our research and development workflows to accelerate scientific discovery and improve operational efficiency," said Peter Bains, Managing Director and CEO of Syngene International. "These capabilities not only enhance throughput and reproducibility but also allow our teams to focus on high-value scientific problem-solving to support our customers."
Bains emphasized the strategic importance of the peptide laboratory investment: "Peptides are increasingly vital in therapeutic development and this specialized facility enables us to support our partners with end-to-end capabilities—from synthesis and purification to characterization and early-stage development. By combining automation with scientific expertise, we are creating a robust platform to accelerate therapeutic innovation and deliver greater value to our clients with end-to-end capabilities, all under one roof."
Comprehensive Service Platform
The upgrades strengthen Syngene's position as an integrated service provider, connecting discovery to downstream development and manufacturing. With over 5,600 scientists and 2.5+ million square feet of specialized facilities, the company serves approximately 400 global customers across pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.
The enhanced capabilities are designed to boost scalability, cost-efficiency, and data quality across therapeutic innovation projects, supporting clients in bringing novel therapies to market faster through improved operational efficiency and scientific excellence.
